Clinical Pharmacokinetics of Pravastatin
- 1 December 2000
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 39 (6) , 397-412
- https://doi.org/10.2165/00003088-200039060-00002
Abstract
Pravastatin, one of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) widely used in the management of hypercholesterolaemia, has unique pharmacokinetic...Keywords
This publication has 92 references indexed in Scilit:
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- AtorvastatinDrugs, 1997
- FluvastatinDrugs, 1996
- Effect of Food on the Bioavailability of Atorvastatin, an HMG‐CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 1995
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 1994
- Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal ImpairmentThe Journal of Clinical Pharmacology, 1992
- PravastatinDrugs, 1991
- Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and LovastatinThe Journal of Clinical Pharmacology, 1990
- Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986